Synlogic, Inc. (NASDAQ:SYBX – Get Free Report) crossed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $1.43 and traded as low as $1.34. Synlogic shares last traded at $1.39, with a volume of 7,571 shares trading hands.
Synlogic Stock Performance
The business has a 50 day moving average of $1.43 and a 200-day moving average of $1.47. The company has a market capitalization of $16.26 million, a P/E ratio of -0.33 and a beta of 0.80.
Synlogic (NASDAQ:SYBX – Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.17. As a group, equities analysts forecast that Synlogic, Inc. will post -2.71 EPS for the current fiscal year.
Synlogic Company Profile
Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.
Read More
- Five stocks we like better than Synlogic
- How to Evaluate a Stock Before Buying
- ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains
- Canadian Penny Stocks: Can They Make You Rich?
- Microsoft and Meta’s AI Investment Plans Are Full Steam Ahead
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Beyond Self-Driving Cars: Factory Automation Takes Center Stage
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.